JP2024513247A5 - - Google Patents

Info

Publication number
JP2024513247A5
JP2024513247A5 JP2023561333A JP2023561333A JP2024513247A5 JP 2024513247 A5 JP2024513247 A5 JP 2024513247A5 JP 2023561333 A JP2023561333 A JP 2023561333A JP 2023561333 A JP2023561333 A JP 2023561333A JP 2024513247 A5 JP2024513247 A5 JP 2024513247A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
pembrolizumab
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023250 external-priority patent/WO2022216580A1/en
Publication of JP2024513247A publication Critical patent/JP2024513247A/ja
Publication of JP2024513247A5 publication Critical patent/JP2024513247A5/ja
Pending legal-status Critical Current

Links

JP2023561333A 2021-04-08 2022-04-04 抗pd-1抗体の皮下投与によるがんの治療方法 Pending JP2024513247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163172299P 2021-04-08 2021-04-08
US63/172,299 2021-04-08
PCT/US2022/023250 WO2022216580A1 (en) 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (2)

Publication Number Publication Date
JP2024513247A JP2024513247A (ja) 2024-03-22
JP2024513247A5 true JP2024513247A5 (cg-RX-API-DMAC7.html) 2024-05-28

Family

ID=83546458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561333A Pending JP2024513247A (ja) 2021-04-08 2022-04-04 抗pd-1抗体の皮下投与によるがんの治療方法

Country Status (21)

Country Link
US (1) US20250074983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320163A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513247A (cg-RX-API-DMAC7.html)
KR (1) KR20230170029A (cg-RX-API-DMAC7.html)
CN (1) CN117279952A (cg-RX-API-DMAC7.html)
AR (1) AR125296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022254960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020867A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214617A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002976A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013273A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230473A (cg-RX-API-DMAC7.html)
DO (2) DOP2023000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076276A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416385A (cg-RX-API-DMAC7.html)
IL (1) IL307430A (cg-RX-API-DMAC7.html)
JO (1) JOP20230243A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011857A (cg-RX-API-DMAC7.html)
PE (1) PE20240051A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305009A (cg-RX-API-DMAC7.html)
WO (1) WO2022216580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂
WO2026124472A1 (zh) * 2024-12-10 2026-06-18 四川科伦博泰生物医药股份有限公司 治疗组合及其用途和治疗方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物

Similar Documents

Publication Publication Date Title
Kim et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer
JP5765634B2 (ja) 低酸素活性化型プロドラッグを用いるがんの処置
JP2019532051A5 (cg-RX-API-DMAC7.html)
EP3524268A1 (en) Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers
JP2019517549A5 (cg-RX-API-DMAC7.html)
JP2011511072A5 (cg-RX-API-DMAC7.html)
JP2012506448A5 (cg-RX-API-DMAC7.html)
US9205098B2 (en) Anti-cancer therapies
JP2021520406A5 (cg-RX-API-DMAC7.html)
JP2020505425A5 (cg-RX-API-DMAC7.html)
RU2018126829A (ru) Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием
JP2025504278A5 (cg-RX-API-DMAC7.html)
JP2023539589A5 (cg-RX-API-DMAC7.html)
JP2022527334A5 (cg-RX-API-DMAC7.html)
IL307430A (en) Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies
JP2024524461A5 (cg-RX-API-DMAC7.html)
JP2019038797A5 (cg-RX-API-DMAC7.html)
JP2024515879A5 (cg-RX-API-DMAC7.html)
Nie et al. An exploration of Trifluridine/Tipiracil monotherapy and in combination with bevacizumab or immune checkpoint inhibitors for patients with metastatic colorectal cancer: A Real-World study
JP2021523096A5 (cg-RX-API-DMAC7.html)
TWI598095B (zh) 治療或緩解高齡或末期癌症患者用之醫藥組合物
JP2023531090A5 (cg-RX-API-DMAC7.html)
JP2005508323A5 (cg-RX-API-DMAC7.html)
EP3127544B1 (en) Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer
Turkington et al. A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma